Home › ECC - More Setback Leave PI3Ks In Immuno-Oncology's Shadow
 

Keywords :   


ECC - More Setback Leave PI3Ks In Immuno-Oncology's Shadow

2015-09-27 17:27:14| Biotech - Topix.net

Roche must be wondering how its cross-town rival Novartis has managed to show so much progress in the otherwise disappointing PI3K inhibitor class of cancer projects. Its earliest candidate in this class, pictilisib, has stumbled badly in a breast cancer trial at a time when Novartis is preparing to file buparlisib in the same disease.

Tags: leave shadow ecc setback

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
28.04National Coalition to End Period Poverty Launched
28.04PZ Cussons To Sell St. Tropez & Aveda Launches Curl Care Line
28.04Beauty Enthusiasts Eye Burgundy Mascara
28.04Distinctive Assets Distributes Mother\'s Day in Hollywood Celebrity Gift Boxes
28.04Musk in China to discuss full self driving - reports
28.04Weekly Recap: U.K. Government Announces Plastic Wipes Ban; Unicharm Starts Selling Recycled Diaper
28.04'Buying a first home is harder when you're single'
27.04CDC Blames \'Vampire Facials\' for HIV Infections
More »